Yabao Pharma has begun preclinical work on an innovative drug candidate for sepsis based on annexin A5. In 2014, Yabao in-licensed greater China rights to discover, develop and commercialize the technology from Canada's Lawson Health Research Institute. So far, the program has completed discovery validation work. A team led by Dr. Qingping Feng, a scientist at Ontario's Lawson Institute and Western University, discovered the technology.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
